Design of the Retinopathy Dependent Quality of Life measure and Retinopathy Treatment Satisfaction Questionnaire [Abstract 1712] by Woodcock, Alison et al.
Woodcock A, Plowright R and Bradley C (2004) Design of the Retinopathy 
Dependent Quality of Life measure and Retinopathy Treatment Satisfaction 
Questionnaire. Quality of Life Research 13 (9) 1538, Abstract 1105.  
 
http://www.jstor.org/stable/4039127 
 
Poster presented at the ISOQOL 11th Annual Scientific Meeting, Hong Kong, October 
2004. 
Abstract 1105  
 
 
DESIGN OF THE RETINOPATHY DEPENDENT QUALITY OF LIFE 
MEASURE AND RETINOPATHY TREATMENT SATISFACTION 
QUESTIONNAIRE 
Alison Woodcock, Rosalind Plowright, Clare Bradley, Psychology, Royal 
Holloway, University of London, Surrey, UK, Tessa Kennedy-Martin, Global 
Economic Affairs, Lilly, Surrey, UK., Axel Hirsch, Diabetes, Bethanien-
Krankenhaus, Hamburg, Germany, Timothy ffytche, Ophthalmology, 
Hospital for Tropical Diseases, London, UK  
 
 AIMS: Measures of the impact of diabetic retinopathy on quality of life 
(QoL) and satisfaction with diabetic retinopathy treatments are needed to 
evaluate current and future therapies. This study aimed to incorporate 
patients' views in designing measures to meet those needs. METHODS: 
 Qualitative and quantitative methods were used in semi-structured 
interviews with 44 people with diabetic retinopathy (11 in each of 2 UK and 2 
German hospitals). Interviewees described how QoL would be different if 
they did not have diabetic eye problems, their experiences of retinopathy 
treatments and views on possible new therapies. They completed and 
commented on a draft Retinopathy Dependent QoL measure (RetDQoL) 
and Retinopathy Treatment Satisfaction Questionnaire (RetTSQ), each 
modelled on an established diabetes measure (ADDQoL and DTSQ 
respectively). Drafts were revised and translated between centres, 
incorporating patient views. The interviews were content 
analysed. RESULTS: Interviewees were 26 men, 18 women; median age 
60.8 (range: 28-82), with background or proliferative retinopathy ranging in 
severity (1 or 2 eyes); median visual acuity better eye 0.80 (range: 0.0025 
(hand motion only) to 1.20 (6/5 vision)). The 26-domain individualised 
RetDQoL and 13-item RetTSQ have face and content validity for people with 
diabetic retinopathy. Visual impairment, worries and advice to restrict 
movement impaired many aspects of QoL. Satisfaction dimensions included 
treatment effectiveness, emotional and physical experiences (before, during 
and after treatment), information provision and influence over 
treatment. CONCLUSIONS: The RetDQoL and RetTSQ are relevant and 
acceptable to a wide range of people with diabetic retinopathy in two 
European countries. They will be useful in evaluating current and future 
therapies in research and clinical contexts. The next step is to use them in 
trials with numbers sufficient for psychometric validation.  
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